G. Borthakur

Susan O'Brien, Gautam Borthakur, Marina Konopleva, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Cancer.

chronic myeloid leukemia in accelerated or blast phase inhibitors is associated with a poor prognosis among patients with major cytogenetic response with second-generation tyrosine kinase Failure to achieve a complete hematologic response at the time of a

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Blood.

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2006 .

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Leukemia & lymphoma.

A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2007 .

Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)

H. Kantarjian, J. Cortes, G. Borthakur, 2007 .

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2010, Clinical lymphoma, myeloma & leukemia.

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of Hematology & Oncology.

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Journal of Hematology & Oncology.

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations

M. Konopleva, M. Andreeff, K. Patel, 2020, Frontiers in Oncology.

Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Clinical lymphoma, myeloma & leukemia.

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

Xiuqiang Wang, H. Kantarjian, J. Cortes, 2010 .

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

H. Kantarjian, J. Cortes, G. Borthakur, 2008 .

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006 .

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

M. Konopleva, K. Patel, T. Kadia, 2020, Frontiers in Oncology.

Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

Z. Estrov, S. Verstovsek, Koichi Takahashi, 2020 .

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Acta Haematologica.

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

M. Konopleva, Z. Estrov, Xuelin Huang, 2021 .

Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study.

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Running title: Sorafenib in hematologic malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2010 .

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

M. Andreeff, J. Dipersio, O. Frankfurt, 2015 .

Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Clofarabine combinations as acute myeloid leukemia salvage therapy

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008, Cancer.

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

M. Konopleva, M. Andreeff, K. Bhalla, 2019, Journal of Clinical Oncology.

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

M. Konopleva, H. Kantarjian, K. Patel, 2020, American journal of hematology.

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

M. Konopleva, M. Andreeff, K. Bhalla, 2020, Blood cancer discovery.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Z. Estrov, H. Kantarjian, J. Cortes, 2014 .

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Phase I study of s-trans, trans-farnesylthiosalicylic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies

F. Ravandi, G. Borthakur, F. Giles, 2007 .

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction Chemotherapy: a Retrospective Case Control Study.

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

Diamond-Blackfan Anemia Predisposing to Myelodysplastic Syndrome in Early Adulthood.

G. Borthakur, C. Dinardo, R. Kanagal-Shamanna, 2017, JCO precision oncology.

Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.

D. Campana, M. Konopleva, M. Andreeff, 2009 .

Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia

G. Borthakur, A. Tefferi, José A López, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

F. Ravandi, G. Borthakur, C. Bueso-Ramos, 2008, Haematologica.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Andrew B. Leber, Lauren E. Heese, R. Davis, 2019, Cancer cell.

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Z. Estrov, H. Kantarjian, J. Cortes, 2012, Clinical Lymphoma, Myeloma & Leukemia.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy

M. Konopleva, M. Andreeff, G. Borthakur, 2022, Haematologica.

Integrated clinical genotype‐phenotype characteristics of early T‐cell precursor acute lymphoblastic leukemia

G. Borthakur, E. Jabbour, M. J. You, 2022, Cancer.

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2008, Leukemia research.

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

K. Bhalla, K. Patel, T. Kadia, 2022, American journal of hematology/oncology.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, S. Colla, H. Kantarjian, 2018, Blood.

Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study

A. Bagg, D. Arber, G. Borthakur, 2020, American journal of hematology.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

M. Andreeff, H. Kantarjian, J. Cortes, 2017, Blood advances.

Transglutaminase 2 expression in acute myeloid leukemia: Association with adhesion molecule expression and leukemic blast motility

K. Coombes, Nianxiang Zhang, G. Borthakur, 2013, Proteomics.

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia

Hannah C. Beird, G. Peng, G. Borthakur, 2022, Genes.

Mitochondrial ClpP-Media ted Proteolysis Induces Selective Cancer Cell Lethality Highlights

Lauren E. Heese, R. Davis, M. Minden, 2019 .

Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Response kinetics and factors predicting survival in core-binding factor leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2018, Leukemia.

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

C. Cleeland, H. Kantarjian, G. Garcia-Manero, 2013 .

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Z. Estrov, M. Andreeff, H. Kantarjian, 2006 .

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

M. Konopleva, K. Rezvani, H. Kantarjian, 2018, Clinical lymphoma, myeloma & leukemia.

Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

Z. Estrov, M. Andreeff, H. Kantarjian, 2013, British journal of haematology.

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

K. Hess, P. LoRusso, S. Khozin, 2020, British Journal of Cancer.

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy‐induced nausea and vomiting in patients with acute myelogenous leukemia

H. Kantarjian, J. Cortes, G. Borthakur, 2010, Cancer.

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva, H. Kantarjian, J. Cortes, 2020 .

Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.

M. Konopleva, M. Andreeff, H. Kantarjian, 2013 .

Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)

M. Konopleva, H. Kantarjian, J. Cortes, 2016 .

Pulmonary Hypertension Is a Frequent Event in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2010 .

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Naveen Garg, M. Konopleva, Z. Estrov, 2021, JAMA oncology.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

G. Borthakur, M. Keating, J. Burger, 2019, Journal of geriatric oncology.

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

O. Lichtarge, K. Do, M. Andreeff, 2020, Blood Cancer Journal.

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

T. Kadia, F. Ravandi, G. Borthakur, 2022, American journal of hematology.

Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

C. Bloomfield, K. Mrózek, M. Perales, 2020, International journal of laboratory hematology.

Prognosis interfered with by clonal interference.

G. Borthakur, 2018, Blood.

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Suzanne F. Jones, G. Fabbri, G. Borthakur, 2019, Blood.

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation

G. Borthakur, M. J. You, Shaoying Li, 2022, Cancers.

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Kashani, A. Tsimberidou, G. Borthakur, 2015 .

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

E. Estey, A. Tsimberidou, G. Borthakur, 2014, Clinical lymphoma, myeloma & leukemia.

Clofarabine: emerging role in leukemias

H. Kantarjian, G. Borthakur, K. Sampat, 2009, Expert opinion on investigational drugs.

Clofarabine: emerging role in leukemias

H. Kantarjian, G. Borthakur, K. Sampat, 2009 .

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, American journal of hematology.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

A. Verma, G. Borthakur, A. Wei, 2021, Leukemia & lymphoma.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Therapy of acute myelogenous leukemia in adults.

G. Borthakur, E. Estey, 2010, Cancer treatment and research.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

K. Baggerly, M. Konopleva, K. Patel, 2019, Clinical lymphoma, myeloma & leukemia.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

M. Konopleva, T. Kadia, F. Ravandi, 2020, Cancer discovery.

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Philip R. Cohen, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Topoisomerase II inhibitors in AML: past, present, and future

G. Borthakur, N. Pemmaraju, M. Economides, 2019, Expert opinion on pharmacotherapy.

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Blood advances.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Acute myeloid leukemia: current progress and future directions

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood Cancer Journal.

Frontline treatment of acute myeloid leukemia in adults.

M. Konopleva, H. Kantarjian, J. Cortes, 2017, Critical reviews in oncology/hematology.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Blood.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022 .

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

Localization of the Adhesion Receptor Glycoprotein Ib-IX-V Complex to Lipid Rafts Is Required for Platelet Adhesion and Activation

Gautam Borthakur, Jing-Fei Dong, José A. López, 2002, The Journal of experimental medicine.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia

M. Andreeff, G. Borthakur, S. Piya, 2017, Autophagy.

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

G. Morgan, M. Dawson, G. Borthakur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

M. Dawson, M. Tallman, G. Borthakur, 2017 .

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Cancer.

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, American journal of hematology.

The Role of Dasatinib in Patients with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Relapsing after Stem Cell Transplantation (SCT).

H. Kantarjian, J. Cortes, G. Borthakur, 2006 .

Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges

G. Borthakur, M. Alfayez, 2018, Expert review of hematology.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2021, British journal of haematology.

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Blood.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Z. Estrov, Jianhua Zhang, Xingzhi Song, 2019, Blood Cancer Journal.

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

H. Kantarjian, I. Samudio, G. Borthakur, 2010, Leukemia & lymphoma.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

M. Konopleva, H. Kantarjian, F. Ravandi, 2019, Clinical lymphoma, myeloma & leukemia.

Emerging cell cycle inhibitors for acute myeloid leukemia

G. Borthakur, Abdallah Abou Zahr, 2017, Expert opinion on emerging drugs.

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

B. Cheson, M. Minden, M. Berger, 2008, Clinical Cancer Research.

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

G. Borthakur, A. Ferrajoli, M. Siddiqui, 2021, Leukemia research reports.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

G. Borthakur, J. Khoury, N. Pemmaraju, 2017, Blood reviews.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Blood.

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

W. Hung, S. Jiang, J. Cortes, 2017, Scientific Reports.

Apoptosis targeted therapies in acute myeloid leukemia: an update

G. Borthakur, S. Ball, 2020, Expert review of hematology.

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104

D. Campana, M. Konopleva, M. Andreeff, 2011, PloS one.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

H. Kantarjian, J. Cortes, G. Borthakur, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia

G. Borthakur, J. Jorgensen, Sa A. Wang, 2015, Leukemia & lymphoma.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2015, American journal of hematology.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, International Journal of Hematology.

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

H. Kantarjian, J. Cortes, G. Borthakur, 2009, Blood.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Leukemia & lymphoma.

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2023, Cancer.

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

H. Kantarjian, T. Kadia, F. Ravandi, 2021, Cancer.

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival

E. Estey, H. Kantarjian, G. Garcia-Manero, 2008, Cancer.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

J. Issa, H. Kantarjian, F. Ravandi, 2008, Leukemia & lymphoma.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

R. Collins, D. Bottomly, S. McWeeney, 2019, Nature Communications.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

A. Letai, H. Döhner, V. Gaidzik, 2014, Cancer discovery.

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2014, Clinical lymphoma, myeloma & leukemia.

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2.

Y. Qi, K. Bhalla, X. Su, 2021, Blood.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Precision 're'arming of CD33 antibodies.

G. Borthakur, 2013, Blood.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Clinical lymphoma, myeloma & leukemia.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Naveen Garg, Rashmi Kanagal-Shamanna, Prithviraj Bose, 2019, The New England journal of medicine.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

G. Borthakur, N. Short, Avash Das, 2019, Clinical lymphoma, myeloma & leukemia.

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

H. Kantarjian, J. Cortes, F. Ravandi, 2015, Cancer.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood Cancer Journal.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

K. Rezvani, D. Marin, H. Kantarjian, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

Bromodomain inhibitors: what does the future hold?

G. Borthakur, S. Piya, Seemana Bhattacharya, 2018, Clinical advances in hematology & oncology : H&O.

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

G. Borthakur, M. Motwani, R. Gandour-Edwards, 2022, In Vivo.

Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature

G. Garcia-Manero, G. Borthakur, N. Jain, 2008 .

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

M. Konopleva, M. Andreeff, G. Borthakur, 2015, PloS one.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

J. Issa, W. Chung, H. Kantarjian, 2013 .

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

E. Estey, F. Appelbaum, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

H. Kantarjian, F. Ravandi, G. Borthakur, 2009, Leukemia.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Blood.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, International journal of molecular sciences.

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, British journal of haematology.

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

M. Konopleva, G. Garcia-Manero, T. Kadia, 2015 .

Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndrome.

G. Borthakur, N. Daver, T. H. Oo, 2014, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of pegylated interferon alpha-2 a in patients with essential thrombocythemia ( ET ) and polycythemia vera ( PV ) : results of a phase 2 study after a 7-year median follow-up

M. Konopleva, Z. Estrov, H. Kantarjian, 2017 .

Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

J. Issa, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Z. Estrov, T. Kadia, G. Borthakur, 2018, Leukemia.

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53

Z. Estrov, H. Kantarjian, K. Patel, 2019, Blood.

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Naveen Garg, M. Konopleva, Z. Estrov, 2021, Leukemia.

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Z. Estrov, H. Kantarjian, K. Patel, 2018, Blood.

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).

Z. Estrov, H. Kantarjian, G. Borthakur, 2017 .

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors

H. Kantarjian, G. Borthakur, M. Keating, 2007, British journal of haematology.

Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology.

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Stephen M. Shaw, M. Andreeff, J. Dipersio, 2020, Cancer.

Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies

H. Kantarjian, G. Borthakur, M. Keating, 2007, Cancer.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Michael L. Wang, R. Davis, T. McDonnell, 2016, Science Signaling.

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms

G. Borthakur, N. Pemmaraju, N. Chen, 2020, Leukemia & lymphoma.

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, BioMed research international.

AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.

P. Vyas, H. Kantarjian, T. Kadia, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood cancer journal.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

H. Kantarjian, E. Shpall, J. Cortes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

E. Shpall, J. Cortes, F. Ravandi, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

M. Maris, G. Borthakur, C. Cogle, 2022, Blood.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Blood advances.

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2020 .

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Haematologica.

Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutations

G. Borthakur, E. Tallis, 2019, Expert review of hematology.

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

G. Garcia-Manero, T. Kadia, F. Ravandi, 2021, Blood.

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Blood.

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Cancer.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

P. Sharma, M. Konopleva, Z. Estrov, 2019, The Lancet. Haematology.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

P. Venugopal, H. Kantarjian, T. Kadia, 2012 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

M. Konopleva, T. Kadia, F. Ravandi, 2022, Blood advances.

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

M. Konopleva, H. Kantarjian, J. Cortes, 2015 .

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

M. Konopleva, Z. Estrov, M. Andreeff, 2016, Clinical lymphoma, myeloma & leukemia.

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

M. Konopleva, G. Garcia-Manero, E. Shpall, 2022, Journal of Hematology & Oncology.

Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

D. Bergstrom, G. Garcia-Manero, G. Borthakur, 2006 .

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Z. Estrov, S. Colla, H. Kantarjian, 2017, American journal of hematology.

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, S. Verstovsek, F. Ravandi, 2009, Cancer.

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2021, Cancer.

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2020, bioRxiv.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

K. Do, M. Konopleva, H. Kantarjian, 2020, American journal of hematology.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Relapse and death during first remission in acute myeloid leukemia

G. Garcia-Manero, F. Ravandi, G. Borthakur, 2008, Haematologica.

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Outcomes of Patients With Relapsed Core Binding Factor‐Positive Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2018, Clinical lymphoma, myeloma & leukemia.

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

A. Stamatoullas, G. Garcia-Manero, G. Borthakur, 2018, The Lancet. Haematology.

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.

R. Davis, M. Konopleva, M. Andreeff, 2019, The Journal of clinical investigation.

Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation

Jing Wang, G. Borthakur, J. Khoury, 2020, Cancers.

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

G. Garcia-Manero, S. Verstovsek, F. Ravandi, 2020, British journal of haematology.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, International Journal of Hematology.

Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017 .

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

R. Chen, Z. Estrov, H. Kantarjian, 2013, American journal of hematology.

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

A Prognostic Model of Therapy-Related Myelodysplastic syndrome .

Z. Estrov, G. Garcia-Manero, J. Cortes, 2009 .

Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2009 .

Modeling interactions between leukemia‐specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core‐binding factor leukemias

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2009, Genes, chromosomes & cancer.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

R. Davis, M. Andreeff, H. Kantarjian, 2016, Blood.

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Cancer.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2019, American journal of hematology.

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

M. Tallman, G. Borthakur, D. DeAngelo, 2014, PloS one.

Clinical significance of MYC expression in acute myeloid leukemia.

Z. Estrov, P. Fox, H. Kantarjian, 2014 .

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

M. Konopleva, H. Kantarjian, J. Cortes, 2017 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012 .

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia

C. Mullighan, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes

M. Konopleva, G. Garcia-Manero, J. Cortes, 2020, American journal of hematology.

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI

Z. Estrov, H. Kantarjian, J. Cortes, 2008 .

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib

H. Kantarjian, J. Cortes, G. Borthakur, 2008 .

Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012 .

Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).

Z. Estrov, H. Kantarjian, J. Cortes, 2016 .

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

R. Collins, D. Bottomly, S. McWeeney, 2015 .

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2011 .

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

M. Dawson, G. Borthakur, B. Huntly, 2016 .

Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, American journal of hematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.

M. Konopleva, M. Andreeff, G. Borthakur, 2016, Cancer research.

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

Therapeutic targeting of isocitrate dehydrogenase mutant AML

G. Borthakur, P. Boddu, 2017, Expert opinion on investigational drugs.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Development of a Fuel–flexible Updraft Thermal Biomass Gasifier

D. K. Mahanta, G. Borthakur, 2012 .

Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia.

Nianxiang Zhang, M. Konopleva, G. Borthakur, 2009 .

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology/oncology.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

P. Hari, S. Parmar, S. Verstovsek, 2019, Blood.

Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Z. Estrov, H. Kantarjian, F. Ravandi, 2007 .

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

L. Vassilev, M. Konopleva, M. Andreeff, 2010 .

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood Cancer Journal.

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

R. Collins, D. Bottomly, S. McWeeney, 2019, Nature Communications.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Cancer.

A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.

M. Berger, G. Borthakur, A. Raza, 2014, Clinical lymphoma, myeloma & leukemia.

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, G. Borthakur, S. O'brien, 2006 .

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.

G. Garcia-Manero, G. Borthakur, E. Jabbour, 2023, Clinical lymphoma, myeloma & leukemia.

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

G. Borthakur, E. Jabbour, N. Short, 2023, Leukemia & lymphoma.

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

G. Garcia-Manero, J. Cortes, T. Kadia, 2022, American journal of hematology.

High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia–Time to Target Autophagy to Improve Therapy Outcomes?

K. Coombes, Nianxiang Zhang, M. Konopleva, 2011 .

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

M. Konopleva, K. Bhalla, H. Kantarjian, 2023, Haematologica.

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.

C. Mullighan, K. Patel, T. Kadia, 2023, JCO precision oncology.

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff, G. Garcia-Manero, J. Cortes, 2023, Journal of Hematology & Oncology.

AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34).

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Clinical lymphoma, myeloma & leukemia.

Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).

G. Garcia-Manero, E. Shpall, G. Borthakur, 2013 .

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

M. Minden, G. Borthakur, K. Yee, 2020 .

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

Farhad, M. Ratain, R. Larson, 2008, Investigational New Drugs.

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Blood advances.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology/oncology.

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016 .

Lenalidomide as a novel treatment of acute myeloid leukemia

G. Borthakur, Yiming Chen, 2013, Expert opinion on investigational drugs.

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML,

M. Konopleva, M. Andreeff, J. Cortes, 2011 .

PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Leukemia research.

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

P. Sharma, M. Konopleva, Z. Estrov, 2017 .

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2021, Blood.

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

M. Konopleva, H. Kantarjian, E. Shpall, 2023, Blood advances.

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

G. Garcia-Manero, E. Shpall, T. Kadia, 2023, American journal of hematology.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

M. Minden, G. Borthakur, O. Barbash, 2019, Blood.

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2019, Blood.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Synergistic Activation of p53 Family of Proteins by the Combination of Nutlin 3a and SAHA in Acute Myelogenous Leukemia.

M. Konopleva, M. Andreeff, I. Samudio, 2009 .

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

S. Kambhampati, C. McMahon, G. Borthakur, 2022, Blood.

A global study for acute myeloid leukemia with RARG rearrangement

J. Welch, H. Kantarjian, Jiong Hu, 2023, Blood advances.

Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma.

Ankit Srivastava, G. Gudi, G. Borthakur, 2023, Blood.

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

M. Konopleva, K. Bhalla, H. Kantarjian, 2018, Blood.

Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations

G. Garcia-Manero, G. Borthakur, C. Dinardo, 2023, Leukemia.

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

G. Borthakur, K. Rajangam, P. Mcsweeney, 2021, Blood.

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

G. Borthakur, Priyanka Sharma, 2023, Cancer drug resistance.

era: analysis of patient from six trials.

M. Konopleva, P. Jain, F. Ravandi, 2016 .

Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

IDH2 mutations in acute myeloid leukemia

G. Borthakur, C. Dinardo, R. Babakhanlou, 2023, Leukemia & lymphoma.

A Single Case of Rosai–Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine

D. Podoloff, G. Borthakur, N. Daver, 2014, Front. Oncol..

Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML.

E. Estey, M. Konopleva, M. Andreeff, 2005 .

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2016 .

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

G. Garcia-Manero, K. Patel, G. Borthakur, 2022, Blood.

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, The Lancet. Haematology.

Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.

A. Verma, H. Kantarjian, J. Cortes, 2011, Journal of Clinical Oncology.

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, British journal of haematology.

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2018, Blood.

A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia

G. Borthakur, N. Pemmaraju, N. Jain, 2014, European journal of haematology.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Naveen Garg, M. Konopleva, Z. Estrov, 2019, Blood.

Patient with mixed-phenotype acute leukemia with CBFB rearrangement

G. Borthakur, J. Khoury, N. Pemmaraju, 2019, Leukemia & lymphoma.

Role of rituximab in first-line treatment of chronic lymphocytic leukemia

G. Borthakur, Jeffrey C. Bryan, 2010 .

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2009, Blood.

Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.

H. Kantarjian, J. Cortes, F. Ravandi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

M. Andreeff, H. Kantarjian, G. Borthakur, 2016, Blood.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

A. Letai, H. Döhner, V. Gaidzik, 2014, Cancer discovery.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

H. Kantarjian, G. Borthakur, E. Jabbour, 2009, Blood.

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML).

H. Kantarjian, J. Cortes, G. Borthakur, 2007 .

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Leukemia.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

G. Borthakur, J. Khoury, N. Pemmaraju, 2017, Blood reviews.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

J. Issa, Z. Estrov, H. Kantarjian, 2012, Leukemia.

Dasatinib (SPRYCEL®) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).

H. Kantarjian, J. Cortes, G. Borthakur, 2006 .

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).

M. Konopleva, M. Andreeff, H. Kantarjian, 2009 .

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

M. Konopleva, Z. Estrov, H. Kantarjian, 2009 .

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 2012 .

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?

G. Borthakur, Maria Siddiqui, 2023, Expert opinion on pharmacotherapy.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2009, Blood.

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib.

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.

Z. Estrov, G. Garcia-Manero, T. Kadia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies

G. Borthakur, A. Maiti, V. Battula, 2024, Journal for ImmunoTherapy of Cancer.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2020 .

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, American journal of hematology.

The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels

M. Konopleva, H. Kantarjian, T. Kadia, 2021 .

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.

Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

T. Haferlach, M. Andreeff, G. Borthakur, 2022, Blood.

Targeting Polo-like Kinase 4 Triggers Polyploidy and Apoptotic Cell Death in TP53-Mutant Acute Myeloid Leukemia

N. Navin, T. Haferlach, M. Konopleva, 2021, Blood.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

M. Andreeff, O. Frankfurt, A. Nagler, 2014 .

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Andrew B. Leber, Lauren E. Heese, R. Davis, 2019, Cancer cell.

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

K. Bhalla, G. Garcia-Manero, T. Kadia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

H. Kantarjian, G. Garcia-Manero, Koichi Takahashi, 2022, American journal of hematology.

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Leukemia.

Phase I trial of intermittent administration of sorafenib (BAY 43–9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.

T. Kadia, F. Ravandi, G. Borthakur, 2024, Cancer.

Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

M. Konopleva, G. Garcia-Manero, E. Shpall, 2023, American journal of hematology.

Prognostic impact of trisomy 8 cytogenetic abnormality in acute myelogenous leukemia: Analysis of a large cohort (N=2187) of newly diagnosed patients.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.

H. Kantarjian, T. Kadia, F. Ravandi, 2024, British journal of haematology.

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.

T. Kadia, F. Ravandi, G. Borthakur, 2024, Leukemia.

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL)

F. Ravandi, G. Borthakur, N. Vey, 2012 .

Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents.

S. Panowski, R. Başar, K. Rezvani, 2024, Virchows Archiv : an international journal of pathology.

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, Xuelin Huang, 2024, Blood advances.

Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia

G. Borthakur, S. O'brien, 2012 .

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.

S. Parmar, G. Garcia-Manero, S. Verstovsek, 2024, NEJM evidence.

Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor

Z. Estrov, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2006 .

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.

Xuelin Huang, F. Ravandi, G. Borthakur, 2024, Leukemia research.

A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2021, Blood.

Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.

H. Kantarjian, J. Cortes, G. Borthakur, 2007 .

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2023, Blood cancer journal.

Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia.

H. Kantarjian, G. Garcia-Manero, K. Patel, 2023, Blood.

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2023, American journal of hematology.

Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms

M. Minden, G. Borthakur, Aarti Tarkar, 2024, Therapeutic advances in hematology.

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2015, American journal of hematology.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Annals of Hematology.

Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

M. Konopleva, M. Andreeff, H. Kantarjian, 2007 .

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

G. Borthakur, D. Rizzieri, L. Brail, 2016, Leukemia & lymphoma.